See also: » 15.03.2010 - Bananas against AIDS? » 03.03.2010 - UNAIDS partner with rock icon to fight AIDS » 12.01.2010 - UN partners seek to eliminate HIV in children » 24.11.2009 - Global HIV infections down by 17 percent » 23.09.2009 - Report calls for HIV-sensitive laws and policing to combat AIDS » 10.09.2009 - Circumcision cost-effective means to prevent HIV - UN report » 19.05.2009 - Global health advocates call for African voices against Obama's budget cut » 13.03.2009 - New partnership to increase funding for Africa's finght against AIDS Houlihan's coupons

Finn autentiske matoppskrifter fra hele verden på Verdensmat.no: Gazpacho Børek Kartoffelsalat Taboulé Gulasj Albóndigas Cevapi Rougaille Japrak sarma Zwiebelbrot Klopse Giouvetsi Paella Pljeskavica Pica pau Pulpo a la gallega Flammkuchen Langosj Tapenade Chatsjapuri Pasulj Lassi Kartoffelpuffer Tortilla Raznjici Knödel Lentejas Bœuf bourguignon Korianderchutney Brenneslesuppe Proia Sæbsi kavurma Sardinske calamares

Autentiske matoppskrifter fra hele verden finner du på Verdensmat.no: Réunion Portugal Aserbajdsjan Serbia Tyskland Seychellene Bosnia Spania Libanon Belgia India Kroatia Hellas Italia Ungarn Komorene Georgia Mauritius Østerrike Romania Frankrike

afrol News / Destination Santé, 16 February - The Pfizer Laboratories have announced that the American and European drug regulation agencies (the FDA and EMEA) have decided to "fasttrack" evaluation of Maraviroc. This drug could become the first of a new class of treatments against HIV known as anti-CCR5 inhibitors.

Rather than fighting against the AIDS virus through the lymphocytes, drugs of this type prevent entry by the virus produced by cells already infected.

Why "drugs" in the plural? Because although Maraviroc is out in pole position, two other CCR5 drugs had already been developed by Schering-Plough (Vicriviroc) and by GSK (Aplaviroc). However, the development of both these drugs was interrupted at an early stage.

To date more than a thousand patients worldwide have been included in the Maraviroc clinical studies programme which has reached development phase III.

The fact that authorities have decided to fasttrack the evaluation procedure for this drug means in effect that it should be completed within 6 months - a particularly short period for a product whose initial synthesis dates back to only 1997.

By staff writer

© afrol News / Destination Santé

Tweet

Printable version

On the Afrol News front page now

Rwanda

Rwanda succeeds including citizens in formal financial sector afrol News - It is called "financial inclusion", and it is a key government policy in Rwanda. The goal is that, by 2020, 90 percent of the population is to have and actively use bank accounts. And in only four years, financial inclusion has doubled in Rwanda. Read more

Famine warning: "South Sudan is imploding" afrol News - The UN's humanitarian agencies now warn about a devastating famine in Sudan and especially in South Sudan, where the situation is said to be "imploding". Relief officials are appealing to donors to urgently fund life-saving activities in the two countries. Read more

Guinea

Panic in West Africa after Ebola outbreak in Guinea afrol News - Fear is spreading all over West Africa after the health ministry in Guinea confirmed the first Ebola outbreak in this part of Africa. According to official numbers, at least 86 are infected and 59 are dead as a result of this very contagious disease. Read more

Ethiopia

Ethiopia tightens its already strict anti-gay laws afrol News - It is already a crime being homosexual in Ethiopia, but parliament is now making sure the anti-gay laws will be applied in practical life. No pardoning of gays will be allowed in future, but activist fear this only is a signal of further repression being prepared. Read more

Ethiopia

Ethiopia plans Africa's biggest dam afrol News / Africa Renewal - Ethiopia's ambitious plan to build a US$ 4.2 billion dam in the Benishangul-Gumuz region, 40 km from its border with Sudan, is expected to provide 6,000 megawatts of electricity, enough for its population plus some excess it can sell to neighbouring countries. Read more